HHS proposes allowing healthcare providers to decline performing services based on moral or religious objections; HHS secretary nominee will advance to full Senate vote; a government shutdown could have long-lasting public health effects.
The Trump administration will allow healthcare providers to decline to perform services based on moral and religious objections. According to The Wall Street Journal, the move is part of an effort to protect religious rights and rolls back anti-discrimination protections put in place by the Obama administration. Current regulation under the Affordable Care Act prohibits discrimination by healthcare providers who receive money from the federal government. The proposal from HHS would allow providers to decline to perform procedures such as gender reassignment surgery and abortions.
President Donald Trump’s nominee to be the next HHS secretary, Alex Azar, has passed the Senate Finance Committee by a vote of 15 to 12. The vote was mostly along party lines with Senator Thomas R. Carper, D-Delaware, breaking ranks with Democrats to vote with Republicans, reported The Washington Post. During his hearing, Azar said his priorities would be making healthcare more affordable, rewarding Medicare providers for promoting good health, and combatting the opioid epidemic. His nomination will now go before the full Senate for a confirmation vote.
The federal government is again on the brink of a shutdown if Democrats and Republicans do not come to an agreement on a spending deal, and it could have long-lasting public health consequences. STAT reported that if there is a government shutdown, the FDA would have to forgo things like updating medication labels and food safety inspections, and the National Institutes of Health could stop enrolling patients in clinical trials. In addition, the shutdown would occur amid a severe flu season and the CDC would have to furlough key staff. CDC would only have 39% of employees in place and HHS would furlough roughly half of its overall staff.
Dr Chakra Chaulagain: PFS Is the "Bare Minimum," but OS Is Ideal for Choosing Between MM Therapies
March 28th 2024Response rates are important when choosing between therapies to treat multiple myeloma (MM), but improvement overall survival (OS) is the ideal, said Chakra Chaulagain MD, FACP, hematologist/oncologist, Maroone Cancer Center of Cleveland Clinic Florida.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Alopecia Areata Impacts Patient Perception, Quality of Life
March 27th 2024Patients with alopecia areata (AA) often perceive their hair loss as more severe than dermatologists do, leading to increased emotional and social problems. This study highlights the importance of understanding patient perception for better treatment and improved quality of life.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
The Supreme Court seems likely to reject a challenge to the abortion pill mifepristone; the FDA is inspecting far fewer pharmaceutical companies conducting clinical research; AstraZeneca has sued to block an Arkansas law that it said would unlawfully expand the 340B program to include for profit-pharmacy chains.
Read More
Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma
March 27th 2024Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.
Read More